Jon Portis, MD
Ophthalmology · Honolulu, HINPI 1073615514
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,296 of the $19,539 with a category attached, or 88.5%. It is spread thinly across 29 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $5,680 and has fallen 52.6% since, to $2,691 in 2025. Among ophthalmology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $73.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$3K
- Alcon$2K
- Glaukos Corporation$2K
- Aerie Pharmaceuticals, Inc.$2K
- Bausch & Lomb Americas Inc.$2K
- Lensar, Inc.$1K
- plus $8K from 23 others
What the payments were for
- Consulting fees$6003%
- Travel & lodging$1,6248%
- Food & beverage$17,29689%
- Other$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 13 | $2,581 |
| Alcon | 33 | $2,278 |
| Glaukos Corporation | 20 | $1,932 |
| Aerie Pharmaceuticals, Inc. | 23 | $1,901 |
| Bausch & Lomb Americas Inc. | 20 | $1,567 |
| Lensar, Inc. | 4 | $1,412 |
| Amgen(2 entities) | 15 | $1,282 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $925 |
| Tarsus Pharmaceuticals, Inc. | 19 | $831 |
| AbbVie(2 entities) | 30 | $772 |
| Regeneron Healthcare Solutions, Inc. | 4 | $442 |
| Novartis | 14 | $435 |
| Sun Pharmaceutical Industries Inc. | 13 | $414 |
| Dompe US, Inc. | 3 | $362 |
| Sight Sciences, Inc. | 2 | $288 |
| Carl Zeiss Meditec, Inc. | 4 | $272 |
| Oyster Point Pharma, Inc. | 3 | $263 |
| Genentech USA, Inc. | 2 | $253 |
| Rxsight Inc | 3 | $238 |
| Thea Pharma Inc. | 2 | $202 |
| Eyevance Pharmaceuticals LLC | 3 | $198 |
| Kala Pharmaceuticals, Inc. | 8 | $195 |
| NEW World Medical,inc. | 2 | $145 |
| Mallinckrodt Hospital Products Inc. | 1 | $115 |
| Apellis Pharmaceuticals, Inc. | 1 | $112 |
| Johnson & Johnson Vision Care, Inc. | 3 | $54 |
| Shire North American Group Inc | 1 | $37 |
| Welch Allyn | 1 | $19 |
| Harrow Eye, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$1,938
- Tecnis 1-piece IOL$1,731
- Tecnis Multifocal Family of 1-piece IOLS$1,731
- Tecnis Symfony IOL$1,731
- LENSAR LASER SYSTEM$1,412
- Rhopressa$1,087
- TEPEZZA$799
- VYZULTA$639
- XDEMVY$533
- Tecnis IOL$429
- Clareon$414
- iStent inject W$371
- Oxervate$362
- LOTEMAX SM$358
- EYLEA$349
- iStent inject Trabecular Micro-Bypass Stent System$296
- OMNI(R) SURGICAL SYSTEM (US)$288
- enVista MX60 IOL$275
- Tecnis Simplicity$250
- TYRVAYA$240
How this compares
$19,539 in reported general payments places this provider in the 90th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 252 | $154,398 |
| RestasisCyclosporine | 61 | $104,552 |
| XdemvyLotilaner | 37 | $69,615 |
| RhopressaNetarsudil Mesylate | 70 | $54,140 |
| XiidraLifitegrast | 26 | $46,725 |
| LumiganBimatoprost | 47 | $40,192 |
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $35,984 |
| MieboPerfluorohexyloctane/Pf | 37 | $30,791 |
| Alphagan PBrimonidine Tartrate | 35 | $20,400 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 61 | $18,108 |
| TyrvayaVarenicline Tartrate | 12 | $14,399 |
| Timolol Maleate | 157 | $10,915 |
| ZyletTobramycin/Lotepred Etab | 29 | $10,063 |
| Brimonidine Tartrate | 33 | $9,973 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $9,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $1,567 | $231,914315 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $772 | $174,206161 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,901 | $90,124136 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $831 | $69,61537 claims |
| AlconSimbrinza | $2,278 | $18,10861 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $263 | $14,39912 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet | $925 | $10,06329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
- Kenneth ChangHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.